Literature DB >> 29626204

Does lower limb amputation concern all SGLT2 inhibitors?

André J Scheen1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29626204     DOI： 10.1038/s41574-018-0001-9

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  7 in total

Review 1.  Empagliflozin: A Review in Type 2 Diabetes.

Authors:  James E Frampton
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 2.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

3.  Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.

Authors:  Caiyun Zheng; Meimei Lin; Yan Chen; Haiting Xu; Lingqun Yan; Hengfen Dai
Journal:  Cardiovasc Diabetol       Date:  2021-04-22       Impact factor: 9.951

4.  SGLT2 inhibitors and lower limb complications: an updated meta-analysis.

Authors:  Chu Lin; Xingyun Zhu; Xiaoling Cai; Wenjia Yang; Fang Lv; Lin Nie; Linong Ji
Journal:  Cardiovasc Diabetol       Date:  2021-04-28       Impact factor: 9.951

5.  Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.

Authors:  Yen-Chieh Lee; Yaa-Hui Dong; Wei-Shun Yang; Li-Chiu Wu; Jou-Wei Lin; Chia-Hsuin Chang
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988

Review 6.  Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.

Authors:  André J Scheen
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

Review 7.  Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Gian Paolo Fadini; Giulio Marchesini; Fabrizio De Ponti
Journal:  Diabetes Obes Metab       Date:  2018-08-14       Impact factor: 6.577
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.